	ID	1	2 :	3 4	5	6 7	8	9	10 11	12	13 14	15 1	6 17	18 19	20 21	1 22 2	3 24	25 26	27 2	28 29	30 31 3	32 33	34 35	36	37 38	39	40 41	42 43	3 44	45 46	47 48	49 5
	Specialty (1=Consultant Oncologist, 2=Consultant Pathologist, 3=Specialist Oncology																															
	Nurse, 4=Specialist Oncology Pharmacist)	4	4 :	3 1	1	1 1	1	3	3 1	1	1 4	1	1 4	4 3	1 1	1 2	1 1	1 1	1	1 2	2 3	1 1	1 1	1	1 1	2	2 2	2 2	2 2	2 2	2 2	2 2
	Histopathology															1				1	1					1 1	1	1 1	1 1	1	1 1	1 1
S	Molecular Diagnostics															0				0	0					0 0	0	0 1	0 0	0	0 1	1 1
00	Coagulation															0				0	0					0 0	0	0 0	0 0	0	0 0	0 0
	Haematology															0				0	0					0 0	0	0 0	0 0	0	0 0	0 0
Ģ.	Immunology															0				0	0					0 0	0	0 0	0 0	0	0 0	0 0
e de	Toxicology															0				0	0					0 0	0	0 0	0 0	0	0 0	0 0
sts	•																															
Pathologi	None of the above															0				0	0					0 0	0	0 0	0 0	0	0 0	0 0
	Are you currently involved with, or do you have experience with, oesophago-gastric can-	dY \	ΥY	Y	Y Y	′ Y	Y Y	/ Y	Υ	Y Y	Y	Y Y	Y	Y Y	/ Y	Y Y	Y Y	Y	Y Y	Y	Y Y Y	Y Y	Y	Y Y	Y	Y Y	Y	Y Y	Y Y	Y	YY	Y Y
	Do you have experience testing for PDL1 in oesophago-gastric cancers?				T ľ		П	T		T ľ						Y	T			Y	Y					YY	Y	Y Y	YY	Y	Y Y	Y Y
	Where is your primary place of work? (1=England, 2=Scotland, 3=Northern Ireland,				- t						-1-							-1-		1												
	4=Wales)	1 1	1	1 1	1	1 1	1	1	1 1	1	1 2	1	1 1	1 1	1 1	1 1	2 1	1 1	1	1 1	1 1	1 1	1 1	1	1 1	1	2 1	1 1	1 1	1 1	1 1	ا ا ا
	What is the estimated number of cases of oesphago-gastric cancer do you see each	+		1			T T		11				11	77			7-	-1-	H	7		11		Ηİ	1		71		1-1-			+
	year? (1=<20, 2=20-50, 3=>50)	3	3 .	3 2	1	1 2	3	3	3 2	3	2 3	2	2 2	1 3	3 1	3 3	3 2	2 2	2	3 3	2 3	3 3	3 3	3	3 3	2	2 2	3 1	1 2	1 1	2 3	3 2
	1 All patients should be tested for HER2, PD-L1 and MSI/DMMR at time of diagnosis	3	4	4 4	4	1 3	4	1	4 3	4	3 4	3	2 3	1 3	3 4	1 4	1 3	4 3	4	4 1	2 4	3 3	4 4	3	4 4	4	3 4	1 1	3 4	3 3	1 4	1 2 '
<del></del>	2 All patients considered potentially suitable for systemic therapy should be tested for HEF	3 4	4	4 4	4	1 4	4	1	4 3	4	4 4	4	4 3	1 3	3 /	1 4	4 3	4 3	4	4 4	4 3	4 4	3 4	3	4 4	4	3 4	1 3	3 4	3 3	1 4	4
_	3 There is a need for clear guidance on which stage of the pathway PD-L1 testing should it		3 .	4 3	4	3 3	4	1	4 4	3	4 4	4	4 4	1 3	3 1	3 2	3 3	1 3	3	4 3	4 3	3 4	3 4	4	4 4	3	4 3	4 3	3 4	3 3	4 3	4
<u></u>	4 A centralised, testing service can provide more efficiency and quality control in the service		4	4 4	3	4 3	3	1	4 3	4	3 4	4	3 3	3 4	3 /	1 4	1 3	1 3	3	4 3	3 3	4 3	3 4	3	3 3	3	4 3	3 3	3 2	4 3	4 4	<del>     </del>
ě ——	PD-L1 testing should be completed in advance of MDTs to inform decision making	4 3	4 .	4 4	2	4 3	3	1	4 3	2	4 4	9	3 3	3 4	3 4	4 4	4 2	4 3	3	4 3	3 3	4 3	3 4	3	3 3	3	2 2	3 3	3 4	2 2	2 2	, 4 .
₹	6 Ideally, testing should be completed in advance of MDTs to inform decision making	4	4 .	4 4	2	2 4	3	1	4 4	3	2 2	3	3 3	3 4	3 4	9 9	4 2	4 3	2	4 1	3 4	2 2	2 4	2	3 4	3	3 3	2 3	3 4	2 3	3 3	3 -
≥	7 Variance in the testing pathway leads to delays in patients accessing appropriate treatm	- 2	4 .	4 4	- 2	3 4	3	- 1	4 3	3	0 0	3	3 3	0 0	3 3	2	4 3	4 3	3	4 1	2 3	2 2	3 4	- 4	4 4	3	4 0	2 3	3 3	2 3	3 2	, <u>-</u>
Ē	National in the desing pathway leads to delays in patients accessing appropriate treatment.  A delay in the diagnostic process may potentially prevent optimal treatment entirely if the		4 '	4 3	3	4 3	4	- 1	4 3	4	3 3	2	3 3	2 3	3 3	3 3	4 3	4 3	3	4 2	3 3	3 4	3 4	4	4 4	3	4 3	3 3	3 3	3 3	4 2	, ,
) j			4 '	4 4	4	4 3	3	- 1	4 2	3	3 4	3	4 3	3 3	3 4	+ 3	4 3	4 3	3	4 3	4 3	4 3	4 4	4	4 4	4	4 3	3 4	4 3	3 3	3 3	4
1	9 It would be beneficial for automatic transfer of specific tissue cores to be in place for cen		3 .	4 4	4	4 3	3	1	4 4	3	4 3	4	3 3	3 3	3 3	3 4	4 3	4 3	3	4 2	3 3	3 3	4 4	4	4 4	3	4 2	2 3	3 2	3 3	3 2	4
	Treating physicians need to be informed promptly when there is insufficient tissue to sat		4 4	4 4	4	4 4	4	1	4 3	3	4 4	4	4 4	4 3	3 4	1 4	4 2	4 3	3	4 4	4 3	3 4	3 4	3	3 4	4	3 4	4 3	3 4	4 3	4 3	4 4
	11 Reflex testing at the point of diagnosis is more efficient than sequential testing and may	3	3 4	4 4	4	3 3	4	1	4 3	4	2 3	4	3 3	3 3	3 2	2 4	4 4	3 3	3	4 2	4 3	4 2	3 4	2	2 4	3	3 4	4 2	2 4	3 3	3 4	2
	12 Reflex testing at the point of diagnosis is more cost-effective than sequential testing	2	2 4	4 4	4	4 3	4	1	4 3	4	2 3	3	3 3	3 3	3 3	3 4	4 2	3 3	2	4 1	3 3	3 3	2 4	3	3 3	3	3 4	4 2	2 4	3 3	3 4	2 :
	13 Reflex testing at the point of diagnosis is recommended in all patients considered poten	11 3	3 4	4 4	4	4 3	4	1	3 4	4	1 3	3	3 3	3 3	3 4	4	4 3	3 3	3	4 1	4 3	3 3	4 4	4	4 4	3	3 4	4 2	2 4	3 3	4 4	4 3
	14 Biomarker tests should be turned around within 10 working days	3	3 :	3 3	3	4 3	4	1	3 3	3	4 4	4	3 2	4 3	3 4	1 3	4 3	3 3	4	4 3	3 3	4 3	4 4	4	3 4	4	4 3	1 3	3 4	3 3	4 3	4 4
	15 Results of biomarker tests should be available no longer than 5 working days from the d		4 4	4 4	3	3 4	4	1	4 3	3	3 3	4	3 3	1 3	3 3	3 2	4 2	3 3	3	4 1	2 4	3 4	3 4	3	3 4	3	2 2	1 3	3 2	3 3	3 1	4
	16 Either in-house or outsourced, tests need to be delivered by an approved United Kingdom		4 4	4 4	3	3 3	4	1	4 4	3	4 4	4	3 3	3 4	3 4	4 4	3 3	3 3	3	4 4	4 3	2 2	4 4	3	4 4	4	4 3	3 3	3 4	4 3	4 4	4 .
	17 The process from requesting a test to receiving the results is often unduly delayed by log	g 2	3 :	3 3	3	2 3	4	1	4 4	4	3 4	2	3 2	3 2	3 4	1 1	4 2	2 3	3	4 2	3 3	3 3	4 4	4	4 4	3	4 4	3 3	3 3	2 3	3 2	. 4
	18 All test results should be made available on a single, integrated report	3	4 4	4 4	2	4 3	4	1	4 3	3	4 4	4	3 3	3 3	3 4	4 3	4 4	4 3	3	4 3	4 3	3 4	2 4	3	2 4	4	4 4	2 3	3 4	3 3	4 3	4 .
	19 All test results should be with the oncologist prior to the first consultation post-diagnosis	3	4 :	3 4	3	4 3	4	1	4 4	2	3 3	4	3 2	4 3	3 4	4	4 2	4 3	3	4 2	4 3	4 4	3 4	4	4 4	3	3 4	1 3	3 4	2 3	4 3	4 '
	20 If there is insufficient tissue for biomarker testing, this should be discussed at the MDT	4	4 .	4 4	3	4 4	3	1	4 3	3	3 3	3	4 3	3 3	3 4	4 4	4 3	2 3	4	4 4	3 3	3 4	4 4	4	4 4	3	4 3	4 3	3 4	3 3	3 3	4 '
	21 Treatment should be initiated within 30 days of receiving biomarker test results	4	4 .	4 4	4	4 3	3	1	4 2	4	4 4	4	3 3	4 3	3 3	3 2	4 4	4 3	3	4 3	3 3	4 3	2 4	3	3 4	3	3 4	2 3	3 4	4 3	3 3	4 '
	22 Positivity rates should be audited for the specific PD-L1 assay for comparison with litera		4 4	4 4	3	3 3	4	1	4 4	3	2 3	4	3 3	3 3	3 3	3 3	4 3	4 3	3	4 3	3 4	2 3	3 4	4	3 3	3	4 4	3 4	4 4	3 3	4 4	. 4
	23 Clearly defined roles and responsibilities for each stage in the testing pathway would be		4 4	4 4	3	4 3	3	1	4 3	4	4 4	3	3 4	3 3	3 3	3 3	4 3	4 3	3	3 3	3 3	4 4	2 4	4	4 3	3	4 4	3 4	4 4	3 3	3 3	4 1
	24 Lack of co-ordination between disciplines involved in the testing pathway can limit effici-		4 4	4 4	3	3 3	3	1	4 3	4	4 4	3	3 4	4 3	3 3	3 3	4 3	3 3	3	4 3	3 3	3 2	4 4	3	2 4	3	4 3	3 4	4 4	3 3	3 3	4
St.	25 A dedicated coordinator should be in place to plan, request, and coordinate disseminati	i 2	3 4	4 3	3	4 3	4	1	4 4	4	4 3	4	3 3	3 4	3 3	3 3	4 2	3 3	3	4 2	2 4	3 4	4 4	2	4 4	3	3 4	2 3	3 4	3 3	3 3	i 4
÷ 7	26 The MDT is responsible for ensuring that the correct testing pathway is in place	2	4 :	3 4	3	4 3	4	1	4 4	1	4 3	2	3 3	4 4	3 4	1 4	2 3	3 3	3	4 4	3 4	4 4	3 4	4	4 4	3	4 4	2 3	3 4	3 3	4 2	2 3
- F	27 The testing pathway should have agreed and documented time and KPI targets	3	4 :	3 4	4	3 4	4	1	4 3	2	4 3	4	3 3	3 4	3 4	4 3	4 2	4 3	3	4 2	3 3	4 3	2 4	3	3 3	3	4 4	1 3	3 4	3 3	3 3	3
£ 7	28 Testing pathway performance should be measured by the MDT	2	2 :	3 4	3	4 4	4	1	4 4	3	4 3	4	3 3	3 2	3 4	1 2	4 2	2 3	3	4 2	3 3	3 4	3 4	4	4 3	3	3 4	1 3	3 4	2 3	3 3	3 '
ž ,	29 Business cases can benefit the establishment of consistent testing pathways that are eff	fi 3	4 -	4 3	4	2 3	3	1	4 4	3	4 4	3	3 3	4 4	3 4	4 3	4 3	3 3	3	4 3	3 3	3 2	3 4	3	4 3	3	4 4	3 3	3 4	3 3	4 3	4
	30 Collaborative horizon scanning between NHS and industry would be beneficial to help		4 4	4 3	3	4 3	4	1	3 3	4	3 4	3	3 3	3 4	3 3	3 3	4 3	3 3	3	3 3	3 3	3 3	4 4	4	4 3	3	3 3	3 3	3 4	3 3	3 4	4
92	31 Education of the entire MDT is vital to improve NHS system readiness for new tests and	3	4 4	4 4	4	4 4	3	1	4 4	3	3 4	4	3 3	4 4	3 4	1 4	4 4	4 3	3	3 3	3 3	2 4	3 4	3	4 3	3	4 4	4 3	3 4	3 3	4 4	4
	32 Any advent of technology and testing use needs to consider capacity concerns in the Ni		4 :	3 4	3	3 4	4	1	4 3	3	3 4	4	3 3	4 4	3 4	1 4	4 4	4 3	3	3 4	4 3	3 3	4 4	4	3 4	3	3 4	4 3	3 4	4 3	4 2	3
	33 Any advent of technology and testing use needs to consider resource requirements rath		4	4 3	3	3 4	4	1	3 3	2	4 4	4	3 3	4 3	3 3	3 4	4 3	4 3	3	4 4	4 4	4 3	2 4	4	4 3	3	4 4	4 3	3 4	4 3	4 3	4
	34 NHS and NICE need to work more collaboratively so when new therapies are approved		4	4 4	4	4 3	4	1	4 4	3	4 4	3	3 3	4 3	3 4	1 3	4 3	4 3	3	4 4	4 3	3 4	4 4	3	3 4	3	4 4	4 4	4 4	3 3	3 4	1 4
	35 A coordinated industry group to liaise with NHS and policy makers could help support fu		4 4	4 4	4	3 3	4	1	4 3	4	4 4	4	3 3	4 4	3 /	1 2	4 3	4 3	3	4 2	3 3	4 4	4 4	4	3 4	3	3 4	4 3	3 4	3 3	3 4	4 4 3
	36 Artificial Intelligence technologies have the potential to improve the speed with which te		4 .	4 3	3	2 4	3	1	4 4	3	4 3	2	3 4	4 3	3 2	1 2	1 3	4 3	3	1 2	2 3	4 4	4 4	3	3 4	1	3 4	4 3	3 4	4 3	4 3	+ 7 -
		4 2		7 3	3	4	3										1 3	7 3	1 3	71 2	4  3		7 7	3	J 4		J 4	7	J 4	7 3	7 3	